Synergy CHC (SNYR)
NASDAQ:SNYR
Want to see SNYR full AI Analyst Report?
SNYR Stock Chart & Stats
$1.63
$0.16(3.75%)
At close: 4:00 PM EST
$1.63
$0.16(3.75%)
Day’s Range― - ―
52-Week Range$0.19 - $4.00
Previous CloseN/A
Volume8.10K
Average Volume (3M)136.07K
Market Cap
$3.12M
Enterprise Value$29.63M
Total Cash (Recent Filing)$292.12K
Total Debt (Recent Filing)$27.75M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.60
Shares Outstanding14,899,883
10 Day Avg. Volume89,526
30 Day Avg. Volume136,069
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.78
Price to Sales (P/S)0.60
P/FCF Ratio-7.00
Enterprise Value/Market Cap9.51
Enterprise Value/Revenue1.07
Enterprise Value/Gross Profit1.64
Enterprise Value/Ebitda-3.41
Forecast
1Y Price Target
$3.75Price Target Upside130.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.13
Revenue Forecast (FY)$33.67M
Bulls Say, Bears Say
Bulls Say
High Gross MarginA sustained ~67% gross margin indicates strong unit economics in the distribution model, giving the company structural pricing power or favorable product mix. That margin base offers durable runway to restore operating profitability if SG&A and overhead are reduced over the next few quarters.
Committed Equity Line FinancingA 24‑month equity purchase agreement for up to $36M provides durable funding optionality, reducing immediate liquidity crunch and allowing management to pace capital raises. This structural access to public equity capital can support operations and covenant compliance while management executes stabilizing actions.
Loan Amendment Gives Near-term FlexibilityRenegotiated term loan terms and amended amortization give the company breathing room on cash interest and near-term principal, a structural relief that extends runway and lowers immediate default risk, enabling management to pursue equity raises or operational fixes without imminent forced repayment.
Bears Say
Highly Stressed Balance SheetPersistently negative equity and debt far exceeding assets create chronic solvency and refinancing risk. This structural imbalance limits strategic flexibility, increases creditor influence, and raises the likelihood that future capital raises will be dilutive or come with restrictive covenants.
Negative Operating And Free Cash FlowOngoing negative operating and free cash flow mean the business consumes cash rather than self-funds growth or debt reduction. Over months this necessitates repeated external financing, constrains reinvestment, and elevates risk that covenants or investor support may erode under continued cash deficits.
Declining Revenue & Deep LossesFalling revenue combined with wide negative margins and negative EBITDA signal structural demand or cost issues. Without sustained revenue stabilization or material cost cuts, the company faces an uphill multi‑quarter path to profitability, complicating debt servicing and capital strategy.
Synergy CHC News
SNYR FAQ
What was Synergy CHC’s price range in the past 12 months?
Synergy CHC lowest stock price was $0.18 and its highest was $4.00 in the past 12 months.
What is Synergy CHC’s market cap?
Synergy CHC’s market cap is $3.12M.
When is Synergy CHC’s upcoming earnings report date?
Synergy CHC’s upcoming earnings report date is Nov 12, 2026 which is in 137 days.
How were Synergy CHC’s earnings last quarter?
Currently, no data Available
Is Synergy CHC overvalued?
According to Wall Street analysts Synergy CHC’s price is currently Undervalued.
Does Synergy CHC pay dividends?
Synergy CHC does not currently pay dividends.
What is Synergy CHC’s EPS estimate?
Synergy CHC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Synergy CHC have?
Synergy CHC has 14,899,883 shares outstanding.
What happened to Synergy CHC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Synergy CHC?
Currently, no hedge funds are holding shares in SNYR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Synergy CHC
Synergy CHC Corp. operates as a distributor of diverse consumer health, beauty, and lifestyle merchandise across the United States, Canada, and the United Kingdom. The company's brand portfolio features FOCUSfactor, specializing in nutritional supplements aimed at enhancing brain function. It also offers the Flat Tummy line, which includes a range of wellness and fashion items such as specialty teas, meal replacement shakes, lollipops, dietary aids, apparel, and exercise accessories. Furthermore, under the Hand MD brand, Synergy CHC Corp. provides anti-aging skincare products, encompassing serums and creams designed for exfoliation, skin repair, and rehydration, as well as hand hygiene products like soaps and sanitizers. These goods are made available to consumers through conventional retail partners and significant television advertising campaigns. The company's skincare range, in particular, is also sold directly via online platforms. Founded in 2010, the firm was originally named Synergy Strips Corp. and rebranded to Synergy CHC Corp. in August 2015. Its primary business operations are based in Westbrook, Maine.
SNYR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture. Material one-time charges (notably a $6.66M bad debt allowance, inventory and media write-offs, and a ~$2.9M license revenue reversal) produced large GAAP losses and pushed operating expenses and adjusted EBITDA down. Offsetting these negatives, management highlighted meaningful strategic progress: beverage early traction (Q1 2026 > all of 2025), Mexico subsidiary and Costco Mexico entry, expanded Kroger distribution, stronger cash and working capital, and management’s contention that normalized gross margins are healthy. Operational risks remain (Flat Tummy weakness, TV advertising not restarted, and elevated inventory levels), but management frames many of the financial setbacks as one-time items with a path to improved normalized performance. Overall, positives and negatives are balanced.View all SNYR earnings summariesSNYR Stock 12 Month Forecast
Average Price Target
$3.75
▲(130.06% Upside)
Technical Analysis
Ownership Overview
34.42% Insiders
4.54% Mutual Funds
10.32% Other Institutional Investors
50.12% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---